Search Result

Isoforms Recommended:	ErbB2/HER2

Results for "

EGFR/HER2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (127) Akt (15) Amino Acid Derivatives (2) Apoptosis (24) Autophagy (10) Bcl-2 Family (1) Btk (5) c-Met/HGFR (9) Calcium Channel (2) Caspase (1) CDK (11) COX (1) Dihydrofolate reductase (DHFR) (3) Drug Isomer (2) ERK (9) HDAC (2) HSP (3) IGF-1R (1) IRAK (2) Isotope-Labeled Compounds (1) Itk (1) JAK (1) Keap1-Nrf2 (1) LYTACs (1) Necroptosis (1) p38 MAPK (9) PACAP Receptor (2) PARP (2) PDGFR (3) PI3K (1) PI4K (1) Potassium Channel (1) PROTACs (3) Raf (1) Reactive Oxygen Species (ROS) (2) Reference Standards (14) SARS-CoV (1) Src (3) Survivin (1) Thymidylate Synthase (2) Trk Receptor (1) VEGFR (11)
By Research Areas:	Cancer (130) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (1) Neurological Disease (6)
Click Chemistry:	Azide (2) Alkynes (1)

137

Inhibitors & Agonists

Screening-Bibliotheken

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: EGFR

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-10261

Afatinib Maximum Cited Publications 103 Publications Verification BIBW 2992	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and *HER2), with IC₅₀* values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-32721

Neratinib 20+ Cited Publications HKI-272	EGFR	Cancer
Neratinib (HKI-272) is an orally available, irreversible, highly selective *HER2* and *EGFR* inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-148810

Zongertinib 1 Publications Verification BI 1810631	c-Met/HGFR	Cancer
Zongertinib (BI 1810631) is a potent and selective *HER2* and *EGFR* tyrosine kinase inhibitor with IC₅₀ values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors .

HY-10261A

Afatinib dimaleate Maximum Cited Publications 103 Publications Verification BIBW 2992MA2	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and *HER2), with IC₅₀* values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-132842

Sunvozertinib 4 Publications Verification DZD9008	EGFR Btk	Cancer
Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC₅₀s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52) .

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of *EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-104065

Pyrotinib 15+ Cited Publications SHR-1258	EGFR	Cancer
Pyrotinib (SHR-1258) is a potent and selective *EGFR/HER2* dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-32721B

Neratinib maleate 20+ Cited Publications HKI-272 maleate	EGFR	Cancer
Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective *HER2* and *EGFR* inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-135815

Mobocertinib 10+ Cited Publications TAK-788; AP32788	EGFR	Cancer
Mobocertinib (TAK-788) is an orally active and irreversible *EGFR/HER2* inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type *EGFR*. Mobocertinib can be used in NSCLC research .

HY-10223

CUDC-101 5+ Cited Publications	EGFR HDAC	Cancer
CUDC-101 is a potent inhibitor of HDAC, *EGFR, and HER2* with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-164718

Sevabertinib BAY 2927088	EGFR	Cancer
Sevabertinib (BAY 2927088) is an orally active and reversible dual *EGFR-HER2* inhibitor (IC ⁵⁰ <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer .

HY-13501

Mubritinib 5+ Cited Publications TAK-165	EGFR	Cancer
Mubritinib (TAK-165) is a potent and selective *EGFR2/HER2* inhibitor with an IC₅₀ of 6 nM.

HY-136789

Tuxobertinib 1 Publications Verification BDTX-189	EGFR	Cancer
Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric *EGFR* and *HER2* oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows K_Ds of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .

HY-10261B

(E/Z)-Afatinib (E/Z)-BIBW 2992	EGFR Apoptosis c-Met/HGFR Akt p38 MAPK Autophagy	Others Cancer
(E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells .

HY-15730

Poziotinib 5+ Cited Publications HM781-36B; NOV120101	EGFR Apoptosis	Cancer
Poziotinib (HM781-36B) is an orally active, irreversible pan-HER inhibitor, which effectively inhibits EGFR ^wt, HER-2 and HER-4 with IC₅₀s of 3.2, 5.3 and 23.5 nM, respectively. Poziotinib (HM781-36B) also shows excellent inhibitory activities against mutated EGFRs, including EGFR ^T790M and EGFR ^L858R/T790M, with IC₅₀s of 4.2 and 2.2 nM, respectively. Excellent antitumor activity .

HY-132842A

(S)-Sunvozertinib (S)-DZD9008	EGFR Btk	Cancer
(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against *EGFR* exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC₅₀=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK .

HY-10530

Varlitinib 2 Publications Verification ASLAN001; ARRY-334543	EGFR	Cancer
Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC₅₀s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively .

HY-17632

Tarloxotinib bromide 1 Publications Verification TH-4000	EGFR	Cancer
Tarloxotinib bromide (TH-4000) is an irreversible *EGFR/HER2* inhibitor.

HY-104065B

Pyrotinib dimaleate 15+ Cited Publications SHR-1258 dimaleate	EGFR	Cancer
Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective *EGFR/HER2* dual inhibitor with IC₅₀s of 13 and 38 nM, respectively .

HY-135815A

Mobocertinib succinate 10+ Cited Publications TAK-788 succinate; AP32788 succinate	EGFR	Cancer
Mobocertinib (TAK-788) succinate is an orally active and irreversible *EGFR/HER2* inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type *EGFR*. Mobocertinib succinate can be used in NSCLC research .

HY-112293

GW2974	EGFR	Cancer
GW2974 is a potent dual inhibitor of *EGFR* and *HER2* with IC₅₀ value of 0.007 μM and 0.016 μM, respectively. GW2974 demonstrates in vitro inhibition of the *EGFR* and *HER2* and inhibits the growth of tumor cell. GW2974 can be used for glioblastoma multiforme (GBM) disease research .

HY-14674

CP-724714 4 Publications Verification	EGFR Apoptosis	Cancer
CP-724714 is a potent, selective and orally active ErbB2 (HER2) tyrosine kinase inhibitor, with an IC₅₀ of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC₅₀=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells. Antitumor activities .

HY-100349

SU4312	PDGFR VEGFR	Cancer
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC₅₀s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC₅₀s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively .

HY-21291

SU-4313	PDGFR EGFR IGF-1R	Cancer
SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC₅₀s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .

HY-15732

BGB-102 JNJ-26483327	EGFR	Cancer
BGB-102 is a potent multi-kinase inhibitor against *EGFR, HER2, and HER4* with IC₅₀s of 9.6 nM, 18 nM and 40.3 nM, respectively.

HY-163428

Perzebertinib ZN-A-1041	EGFR	Inflammation/Immunology Cancer
ZN-A-1041 inhibits *HER2* in BT474 cell and *wt-EGFR* in H838 cells, with IC₅₀s of 9.5 nM and 12 μM respectively. ZN-A-1041 can be used for research of cancer and inflammation .

HY-N1180

Tanshinlactone	SARS-CoV Keap1-Nrf2	Infection
Tanshinlactone is a compound found in Salvia miltiorrhiza with anti-coronavirus (CoV) and anti-tumor activities. Tanshinlactone induces methuocytic cell death (methuosis) by activating the NRF2 pathway, and selectively kills ER ⁺, HER2 ⁺/EGFR ⁺ breast cancer cells. Tanshinlactone is applicable to research related to breast cancer and coronavirus infections .

HY-143319

SPH5030	EGFR	Cancer
SPH5030 is a selective and irreversible *HER2* inhibitor. SPH5030 inhibits HER2 ^WT and EGFR ^WT with IC₅₀s of 3.51 and 8.13 nM, respectively. SPH5030 shows excellent activities against HER2 mutants. SPH5030 can be used for the research of cancer .

HY-111553

TAS0728	EGFR	Cancer
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding *HER2* inhibitor, with an IC₅₀ of 13 nM. TAS0728 also shows IC₅₀s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for *BMX、HER4、BLK、EGFR、JAK3、SLK* and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of *HER2, HER3*, and downstream effectors .

HY-E70715

ERBB2 775YVMA776 Recombinant Human Active Protein Kinase	EGFR	Cancer
The erbB family comprises 4 structurally related receptors: ErbB1 (EGFR), ErbB2 (HER2-neu), ErbB3 and ErbB4. On ligand stimulation, the receptor forms either homodimers or heterodimers, which activate their cytoplasmic domain. ERBB2 775YVMA776 Recombinant Human Active Protein Kinase is a recombinant ERBB2 775YVMA776 protein that can be used to study ERBB2 775YVMA776-related functions .

HY-108931

AG 1406	EGFR	Cancer
AG 1406 (compound M19) is a *HER2* inhibitor, with an IC₅₀ of 10.57 μM for HER2 in BT474 cell and >50 μM for EGFR in EGF-3T3 cell .

HY-10261R

Afatinib (Standard) BIBW 2992 (Standard)	Reference Standards EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-32721R

Neratinib (Standard) HKI-272 (Standard)	Reference Standards EGFR	Cancer
Neratinib (Standard) is the analytical standard of Neratinib. This product is intended for research and analytical applications. Neratinib (HKI-272) is an orally available, irreversible, highly selective *HER2* and *EGFR* inhibitor with IC₅₀s of 59 nM and 92 nM, respectively .

HY-151159

DHFR-IN-4	Dihydrofolate reductase (DHFR) EGFR	Cancer
DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with an IC₅₀ value of 123 nM. DHFR-IN-4 also has inhibitory activity against *EGFR* and *HER2* with IC₅₀s of 246 nM and 357 nM, respectively. DHFR-IN-4 has remarkable broad spectrum cytotoxic potency against cancer cells .

HY-123766

EGFR-IN-99	EGFR	Cancer
EGFR-IN-99 (compound 1a) is a potent *EGFR* and *HER2* Exon 20 insertion mutant inhibitor. EGFR-IN-99 has excellent antiproliferative activity against DFCI127 cells, with an EC₅₀ of 11.5 nM. EGFR-IN-99 can be used for the research of non-small cell lung cancer (NSCLC) .

HY-174414

EGFR/HER2-IN-18	EGFR	Cancer
EGFR/HER2-IN-18 is a stable *EGFR/HER2* dual inhibitor with IC₅₀ values of 0.09 (EGFR) and 0.08 μM (HER2) respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer .

HY-174841

EGFR/HER2-IN-19	EGFR	Cancer
EGFR/HER2-IN-19 (Compound L1) is a dual inhibitor against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-19 is promising for research of cancers driven by EGFR/HER2 .

HY-172623

EGFR/HER2-IN-17	EGFR Caspase Apoptosis Bcl-2 Family	Cancer
EGFR/HER2-IN-17 (Compound 7h) is a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). EGFR/HER2-IN-17 inhibits cancer cell proliferation. EGFR/HER2-IN-17 interacts with the binding pockets of EGFR and HER2, activating caspase-3 and caspase-8, and decreases the expression of Bcl-2, thereby inducing apoptosis. EGFR/HER2-IN-17 is promising for research of cancers .

HY-147798

EGFR/HER2/CDK9-IN-3	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-3 (Compound 10) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 191.08, 132.65, and 113.98 nM, respectively. EGFR/HER2/CDK9-IN-3 exhibits remarkable antitumor activity .*

HY-147796

EGFR/HER2/CDK9-IN-1	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 90.17, 131.39, and 67.04 nM, respectively. EGFR/HER2/CDK9-IN-1 exhibits remarkable antitumor activity .*

HY-147797

EGFR/HER2/CDK9-IN-2	EGFR CDK	Cancer
EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC₅₀*s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity .*

HY-P991234

COVA208	EGFR p38 MAPK PI3K Akt	Cancer
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets *HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive* breast cancer, gastric cancer, and colorectal cancer .

HY-147994

EGFR/HER2-IN-5	EGFR	Cancer
EGFR/HER2-IN-5 (compound 6h) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-5 inhibits *EGFR* with an IC₅₀ value of 1.01 nM and demonstrates potent *EGFR* kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-5 has potent antitumor efficacy in vivo and can be used for lung cancer research .

HY-147992

EGFR/HER2-IN-4	EGFR	Cancer
EGFR/HER2-IN-4(compound 6d) is an orally active irreversible dual inhibitor. EGFR/HER2-IN-4 inhibits *EGFR* with an IC₅₀ value of 0.6 nM and demonstrates potent *EGFR* kinase inhibitory activities on L858R and T790M mutations. EGFR/HER2-IN-4 has potent antitumor efficacy in vivo and can be used for lung cancer research .

HY-153856

TAS2940	EGFR	Cancer
TAS2940 is a brain-penetrable, orally active, irreversible and selective pan-ERBB inhibitor. TAS2940 against wild-type HER2, HER2 V777L, and A775_G776insYVMA with IC₅₀ values of 5.6 nM, 2.1 nM, and 1.0 nM, respectively. TAS2940 can be used for the study of tumors with HER2 and EGFR aberrations .

HY-10261E

(R)-Afatinib (R)-BIBW 2992	EGFR c-Met/HGFR p38 MAPK	Cancer
(R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of?ErbB?family (EGFR?and?HER2), with?IC₅₀?values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for?EGFR ^wt, EGFR ^L858R,?EGFR ^L858R/T790M?and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung?cancer?(NSCLC) and gastric?cancer .

HY-162623

EGFR/HER2-IN-15	EGFR	Cancer
EGFR/HER2-IN-15, a dihydropyrimidine, is a potent *EGFR/HER2* inhibitor. EGFR/HER2-IN-15 significantly inhibits EGFR ^wt activity with an IC₅₀ of 37.21 nM. EGFR/HER2-IN-15 has anticaner effects .

HY-10261D

Afatinib oxalate BIBW 2992 oxalate	EGFR Autophagy Apoptosis c-Met/HGFR Akt	Cancer
Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and *HER2), with IC₅₀* values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-157399

EGFR/HER2-IN-10	EGFR	Cancer
EGFR/HER2-IN-10 (compound 9F) is a potent and selective dual *EGFR/HER2* inhibitor with IC₅₀s of 2.3 nM and 234 nM for EGFR and HER2, respectively. EGFR/HER2-IN-10 shows an effective antiproliferative action against prostate carcinoma .

HY-151156

EGFR/HER2-IN-6	EGFR Apoptosis	Cancer
EGFR/HER2-IN-6 (compound 43) is an *EGFR/HER2* and DHFR inhibitor. EGFR/HER2-IN-6 inhibits EGFR kinase, HER2 kinase and DHFR with IC₅₀s of 0.122, 0.078 and 0.585 μM, respectively. EGFR/HER2-IN-6 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .

Art. -Nr.	Produktname

HY-L177

Antibody Inhibitor Library

1,777 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 1,777 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Art. -Nr.	Produktname	Target	Research Area

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-P1845

PACAP-38 (31-38), human, mouse, rat	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat does not bind to the PACAP receptor .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat TFA does not bind to the PACAP receptor .

HY-P11757

Cyclo[K(N3)larllt]	EGFR	Cancer
Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a K_d value of 5.09 μM, and exhibits binding selectivity toward homologous proteins *HER2* and *HER3. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR* overexpression. Cyclo[K(N3)larllt] can be used in the research of colorectal cancer .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

Art. -Nr.	Produktname	Target	Research Area	Image

HY-P99275

Patritumab 1 Publications Verification AMG-888; U3-1287	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of *EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis* and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P991234

COVA208	EGFR p38 MAPK PI3K Akt	Cancer
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets *HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive* breast cancer, gastric cancer, and colorectal cancer .

HY-P991977

BSI-001 5G9	EGFR Apoptosis PARP Akt ERK	Cancer
BSI-001 (5G9) is a *HER2*-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of *EGFR, HER3, AKT* and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of *HER2*-positive breast cancer and *HER2*-overexpressing gastric cancer .

HY-P991780

Anti-Mouse HER2 (domain I) Antibody (H2Mab-304)	EGFR	Cancer
Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) reacts with domain I of mouse HER2. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-N1073

Wighteone 1 Publications Verification 6-Isopentenylgenistein; Erythrinin B	Leguminosae Genista ephedroides DC. Plants Isoflavones Source Classification	Apoptosis EGFR HSP ERK Akt
Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFR ^L858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of *EGFR, and thereby inhibits the downstream ERK* and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFR ^L858R/T790M mutation, and fungal infections .

HY-N1180

Tanshinlactone	Structural Classification Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants Source Classification	SARS-CoV Keap1-Nrf2
Tanshinlactone is a compound found in Salvia miltiorrhiza with anti-coronavirus (CoV) and anti-tumor activities. Tanshinlactone induces methuocytic cell death (methuosis) by activating the NRF2 pathway, and selectively kills ER ⁺, HER2 ⁺/EGFR ⁺ breast cancer cells. Tanshinlactone is applicable to research related to breast cancer and coronavirus infections .

Species:	Human (2) Cynomolgus (2)
Tag:	His (3) Avi (3) Fc (1)
Source:	HEK293 (4)

Art. -Nr.	Compare	Produktname	Species	Source	Image

HY-P700887

	HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; NGL; TKR1; ERBB2; NEU; ENV; ENVW; ERVWE1; HERV7Q; HERVW	Cynomolgus	HEK293
	Erb-b2 receptor tyrosine kinase 2 is a member of EGFR family. Erb-b2 receptor tyrosine kinase 2 is over-expressed in the tumors of many types of cancers. Erb-b2 receptor tyrosine kinase 2 enables ATP binding and transmembrane receptor protein tyrosine kinase activity. HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, His) is the recombinant cynomolgus-derived HER2/CD340 protein, expressed by HEK293 , with C-His labeled tag.

HY-P705027

	HER2/CD340 Protein, Cynomolgus (Biotinylated, HEK293, Fc-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; NGL; TKR1; ERBB2; NEU; ENV; ENVW; ERVWE1; HERV7Q; HERVW	Cynomolgus	HEK293

HY-P78138

	HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P78451

	HER2/CD340 Protein, Human (HEK293, His-Avi) CD340; EGFR2; ErbB2; HER2; HER-2; HERstatin; MLN 19; MLN19; Neu Oncogene; NEUHER-2/neu; NGL; p185erbB2; TKR1; ERBB2; HER-2/neu; NEU; ENV; ENVW; ERVWE1; HERV-7q; HERV-W-ENV; HERV7Q; HERVW; HERVWENV	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (HEK293, His-Avi) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Art. -Nr.	Produktname	Chemical Structure

HY-32721S

Neratinib-d6
Neratinib-d₆ (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.

HY-10261S1

Afatinib-d4
Afatinib-d₄ is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

HY-10261AS

Afatinib-d6 dimaleate
Afatinib-d₆ (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC₅₀s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively .

Art. -Nr.	Produktname		Classification